key: cord-0707914-fep68ex9
authors: Mahdizade Ari, Marzie; Mohamadi, Mohamad Hosein; Shadab Mehr, Negar; Abbasimoghaddam, Sajjad; Shekartabar, Amirhosein; Heidary, Mohsen; Khoshnood, Saeed
title: Neurological manifestations in patients with COVID‐19: A systematic review and meta‐analysis
date: 2022-04-06
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24403
sha: d430ca60196ad2a708c4e4a3d831ae393d086842
doc_id: 707914
cord_uid: fep68ex9

INTRODUCTION: The intensification of coronavirus disease 2019 (COVID‐19) complications, severe symptoms, and high mortality rate has led researchers to focus on this significant issue. While respiratory and cardiac complications have been described as high‐risk manifestations in patients with COVID‐19, neurological complications can also enhance mortality. This study aimed to evaluate the prevalence of neurological complications arises from SARS‐CoV‐2 and assess the mortality rate from neurological complications. MATERIAL AND METHODS: Literature review was conducted by searching in PubMed/Medline, Web of Sciences, and Embase. After performing search strategies with relevant terms, a number of articles were excluded, including review articles, systematic review or meta‐analysis, duplicate publication of same researchers, congress abstracts, animal studies, case reports, case series, and articles reporting a history of neurological features prior to COVID‐19 infection. After retrieving the data, statistical analysis was performed using the STATA Version 14 software. RESULTS: From 4455 retrieved publications, 20 articles were selected for further analysis. Among 18,258 included patients, 2791 showed neurological symptoms, which were classified into different groups. Headache, confusion, and fatigue were reported as the most non‐specific neurological features in confirmed COVID‐19 patients. Psychiatric symptoms, CNS disorders, cerebrovascular disorders, CNS inflammatory disorders, PNS disorders, neuromuscular disorders, etc., were defined as specific neurological manifestations. The pooled prevalence of neurological manifestations and mortality rate of COVID‐19 patients with neurological features were estimated to be 23.0% (95% CI: 17.8–29.2) and 29.1% (95% CI: 20.3–39.8), respectively. CONCLUSION: Neurological manifestations may commonly happen in patients with COVID‐19. This study reported a high prevalence of neurological complications and mortality rates in COVID‐19 patients. Therefore, patients with COVID‐19 who indicated neurological symptoms should be taken seriously and should receive early treatment to prevent undesirable events.

The coronavirus disease 2019 (COVID- 19) , an infection induced by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), originated in Wuhan, China in December 2019. This disease spread rapidly around the world and caused the deaths of millions of people. 1 In 2002 and 2012, the outbreaks of other members of this betacoronavirus, namely SARS-CoV and MERS-CoV, were, respectively, recorded. 2 According to the WHO report, more than 100 million cases were infected with SARS-CoV-2, and about four million deaths from COVID-19 were reported.

(CDC), COVID-19 is accompanied by three main symptoms, including common (fever, dry cough, headache, and fatigue), less common (pain, sore throat, diarrhea, and loss of taste and appetite), and severe (shortness of breath, chest pain, and dysfunction in speech).

The disease is not limited to the respiratory system, but it encompasses a wide range of cardiovascular and neurological complications. 3 Search of genomes and coronavirus-related sequences in the cerebrospinal fluid (CSF) verifies this assumption. 4 The intensified complications, severe symptoms, and high mortality rate of COVID-19 have forced special attention to this disease. While respiratory and cardiac complications are considered high risks in patients with COVID-19, neurological complications have also been demonstrated to enhance mortality rate. 5 SARS-CoV-2, the same as SARS-CoV and MERS-CoV viruses, has several routes of entry to central nervous system (CNS) and

peripheral nervous system (PNS), including olfactory pathway and gut-brain axis as the neural pathways 6 and blood-brain barrier (BBB) as hematogenous pathway. 7, 8 These accessibilities are provided by the expansion and expression of angiotensin-converting enzyme 2 (ACE2) on nerve tissues and capillary endothelial tissues, 9 which are also present in brain endothelial cells and small intestine. 10 This notion corroborates earlier investigations that stated reduced RNA tracking in CSF may be the indication of direct SARS-CoV-2 invasion to nervous tissue in the cell-to-cell spread pattern. 11, 12 However, inaccessibility to virus in the normal range of detection via the analysis of CSF samples and also the presence of hemoproteins product may relate to the lack of identifying SARS-CoV-2 in these samples. 13 The first step in brain damage caused by the SARS-COV-2 is triggering the inflammatory response of cytokines (e.g., IL-6, IL-12, and TNFα) after binding the virus to ACE2 and its proliferation in the CNS. 5, 10 Neurological complications that affect CNS, PNS, and musculoskeletal system 8,13 entail impaired consciousness, stroke, anosmia, ataxia, and seizures, acute necrotizing encephalopathy, meningoencephalitis, and Guillain-Barre syndrome (GBS), recognized as PNS-related symptoms, as well as Miller Fisher syndrome and hypogeusia that happen as a result of SARS-CoV-2 entry to peripheral neurons. 14 Collectively, the direct invasion of virus, immune-induced complications, and cytokine storms are the main pathogenesis of the SARS-CoV-2. It is surmised that the immune system role is central to the development of neurological complications caused by this virus. 15, 16 The present study aimed to evaluate the prevalence of neurological manifestations and mortality rate in patients with COVID-19.

The present systematic review was conducted by relying on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements. 17 

Our systematic search was performed using databases viz PubMed/ Medline, Web of Sciences, and Embase from January 1, 2019 to March 7, 2021. The terms employed in the search strategies were as follows: "Central nervous system" or "brain" or "neurologic" or "CNS "and "COVID-19" or "severe acute respiratory syndrome coronavirus 2" or "novel coronavirus" or "SARS-CoV-2" or "SARS2" or"2019-nCoV" or "nCoV disease" or "coronavirus disease-19" or "coronavirus disease 2019" or "2019 novel coronavirus" or "Wuhan coronavirus" or "Wuhan seafood market pneumonia virus" or "Wuhan pneumonia". There were no language restrictions; however, for non-English articles, online translation systems were utilized. Besides, no limitations were considered for the location and type of articles.

neurological features and were positive for SARS-CoV-2. Reverse transcription-polymerase chain reaction (RT-PCR) was the main diagnosis method of confirming COVID-19, but multiple studies added serological tests and computed tomography (CT) scan, as well.

Regarding nervous system involvement, we took into consideration all reported neurological findings, comprising CNS and PNS symptoms, CNS inflammatory features, and cerebrovascular attributes, as well as neuromuscular, psychiatric, and non-specific symptoms.

All the methods used for the diagnosis of neurological symptoms were viewed as qualified. The exclusion of articles was based on any of the following papers: Review articles, systematic review or meta-analysis, duplicate publication of same researchers, congress abstracts, and articles reporting a history of neurological features prior to COVID-19 infection. Likewise, animal studies, case reports, and case series were excluded.

The data retrieved for each article were as follows: first author's name, location, publication time, sample size, number of COVID-19 patients, gender, median age, COVID-19 diagnosis method, neurological manifestations, diagnosis method of neurological findings, and number of deaths. Four authors extracted the information from the full-text of 20 selected studies, independently. Inconsistencies between reviewers were resolved by consultation. Table 1 shows the extracted data.

Analysis of data was performed by using STATA (version 14, IC; Stata Corporation, College Station, TX, USA), and the prevalence of neurological complications was estimated with confidence intervals (CIs) of 95%. The pooled frequency was calculated by a random effect model with 95% CI. Publication bias was also assessed by Begg's and Egger's tests, and p value <0.05 was considered an indication of statistically significant publication bias.

A total of 4455 studies were collected from three databases. After the removal of duplicates, articles were screened for title and abstract, and 119 papers met the criteria. Thereafter, the full-text of these studies, which all reported the neurological symptoms of COVID-19 infection, were evaluated. Following the exclusion of irrelevant studies, only 20 articles were identified as qualified for final extraction and analysis ( Figure 1 ). These papers were appropriate for systematic review and entered into data extraction. Eighteen of these clinical studies used various methods, such as brain CT, MRI, EGG, and CSF for the diagnosis of neurological manifestations . 8,10,11,18-32 However, two other studies performed only clinical neurological exams. 4, 33 In all 20 studies, RT-PCR was examined using nasopharyngeal swab, but nine 8, 10, 18, [23] [24] [25] [26] 29, 30 and three 22, 27, 28 studies employed chest CT scan and ELISA, respectively, to confirm COVID-19. Ten articles were originated from Europe, five from the USA, two from China, and others from Brazil, Pakistan, Egypt, and Chile. The information of these 20 studies is summarized in Table 1 .

A variety of neurological findings were reviewed and classified into different groups ( Table 2) . Among 20 articles, 18,258 cases were found by RT-PCR test to be positive for SARS-CoV-2 (COVID- 19) , and 2791 of patients had various neurological manifestations. The overall frequency of neurological symptoms in COVID-19 patients was 15.28%. Additionally, 12 articles reported mortality. Among the 2791 patients, 582 succumbed in hospital; therefore, the total mortality rate was 20.85%.

Since the emerging COVID-19 infection, a noticeable large number of studies have focused their attention on this outstanding issue; thus, various symptoms and signs have been reported for this disease.

Based on the literature, headache, 34 confusion, 35 and fatigue 36, 37 are the most common symptoms. In addition, altered mental status is realized as a common initial presentation in COVID-19 patients. 38 Our results are in line with these findings. Among 20 included studies we reviewed, 13, 5, 3, 1, 6, and 6 studies reported headache, dizziness, weakness, fatigue, confusion, and altered mental status, respectively, as the most frequent symptoms. Five studies reported the observation of neuropathy features in 87 of 977 examined patients. 11, 19, 23, 26, 29 Two articles stated 45.76% (81/177) with sleep disorder, 8, 33 and one of these studies mentioned daytime sleepiness in 36.17% (34/94). 33 The relative frequency of reduced reflex symptoms was 50% (2/4), standing as the most common symptoms.

However, it could not be considered a notable manifestation due to the inadequate number of cases. 27 Hemiparesis and hemiplegia were detected in 14.81% (4/27), as reported by one study. 25 

Evidence has shown that coronavirus can target CNS and exert its neurotropic effects. 39 On the basis of this review, a broad spectrum of CNS manifestations was reported in coronavirus-infected patients and classified into CNS disorders, CNS inflammatory disorders, and cerebrovascular disorders. The number of stroke (11.18%), coma (6.55%), and seizure/convulsion (7.71%) patients were much more than any other CNS disorders. Thirteen studies reported at least one of these disorders in COVID-19 patients. 4, 10, 11, 19, 20, [22] [23] [24] [29] [30] [31] [32] Remarkably, stroke, as a major concern in COVID- 19 

Nine studies reported 160 anosmia/hyposmia cases out of 768 26 and psychomotor agitation 23 were also reported by three articles. 

In total, 12 studies reported the number of deaths as the outcome.

The pooled mortality of COVID-19 patients with neurological features was estimated to be 29.1% (95% CI: 20.3-39.8). Figure 4 displays the meta-analysis of the overall mortality rate. As indicated in Figure 5 , no evidence of publication bias was found (p = 0.54 and p = 0.57 for Begg's rank correlation analysis and Egger's weighted regression analysis, respectively). 

According to the quality assessment of the 20 included studies, all of them had a low risk of bias. We summarized the results of the critical appraisal (JBI checklist) of included studies in Table S1 . There is a direct relationship between headache and inflammation caused by COVID-19 and high levels of IL-6 as a marker of pain. 47 One of the significant findings of the present study was the mortality rate (29.1%) due to neurological complications of COVID-19.

Other complications of COVID-19 have been described as respiratory and non-respiratory complications, which there is no doubt that respiratory complications have more severe outcome, as stated by Vakili and co-workers. 48 However, non-respiratory complica- cohort study. In-hospital death of patients with COVID-19 is also related to sex (i.e., males), diabetes mellitus, history of chronic pulmonary disease, increasing age, D-dimer, body mass index, sequential organ failure assessment scores, and so forth. The number of neurological manifestations such as stroke and altered mentation (p < 0.05) in COVID-19 patients may be a high-risk factor for hospitalrelated mortality. 31, 50 Considering the reduced mortality rate of patients who were admitted in ICU, dexamethasone showed effective outcomes due to its inhibitory activity against immune response, which is essential for the inflammatory conditions. However, these corticosteroids induce neurological manifestations in long-term administration. 51 The mortality rate was higher in patients with the in vitro symptoms of COVID-19 who suffered from neurological complications. This finding agrees with the study conducted by Frontera et al. 19 who highlighted that patients with stroke are more prone to death than those who have stroke but not COVID-19, which is attributed to prolonged hospitalization. 

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update

SARS and MERS: recent insights into emerging coronaviruses

Relation between COVID-19 and Guillain-Barré syndrome in adults: a systematic review

Frequency of neurological presentations of coronavirus disease in patients presenting to a tertiary care hospital during the 2019 coronavirus disease pandemic

Neurologic complications of COVID-19

Neurologic alterations due to respiratory virus infections

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

A prospective clinical study of detailed neurological manifestations in patients with COVID-19

Atypical neurological manifestations of COVID-19

Retrospective observational study of brain magnetic resonance imaging findings in patients with acute SARS-CoV-2 infection and neurological manifestations

Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study

Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)

Neurological manifestations of COVID-19: with emphasis on Iranian patients

SARS-CoV-2 induced neurological manifestations entangles cytokine storm that implicates for therapeutic strategies

SARS-CoV-2 infection: the role of cytokines in COVID-19 disease

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

A prospective study of neurologic disorders in hospitalized patients with COVID-19 in

Assessment of neurological manifestations in hospitalized patients with COVID-19

Brain MRI findings in patients in the intensive care unit with COVID-19 infection

Neurologic features associated with SARS-CoV-2 infection in children: a case series report

Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital

New onset neurologic events in people with COVID-19 in 3 regions in China

COVID-19)-associated encephalopathies and cerebrovascular disease: the New Orleans experience

Surveillance study of acute neurological manifestations among 439 Egyptian patients with COVID-19 in Assiut and Aswan University Hospitals

Neurologic and radiographic findings associated with COVID-19 infection in children

Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome

Neurologic manifestations in 1760 COVID-19 patients admitted to papa Giovanni XXIII hospital

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Neurologic syndromes predict higher in-hospital mortality in COVID-19

Neurological complications among native Americans with COVID-19: our experience at a tertiary care academic hospital in the US

Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection

Prevalence of headache in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of 14,275 patients

The neurological manifestations of COVID-19: a review article

Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med

COVID-19 Fatigue: Not So Fast. American College of Cardiology Foundation

Altered mental status as a novel initial clinical presentation for COVID-19 infection in the elderly

Neurotropic viruses, astrocytes, and COVID-19

COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation

Encephalopathy in patients with COVID-19: 'causality or coincidence?'

Vascularisation of the central nervous system

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Neurological associations of COVID-19

neurologic syndromes predict higher in-hospital mortality in COVID-19

COVID-19 associated myositis with severe proximal and bulbar weakness

Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study

Critical complications of COVID-19: a descriptive meta-analysis study

Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium

Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study

Acute and post-acute neurological complications of COVID-19

Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis

Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

There were some limitations for the current study. First, in addition to the bias of publications, which is common among almost systematic reviews, there were few heterogeneities in the prevalence of neurological complications and the number of studies. Second, inclusion criteria and excluding case reports and non-English studies may lead to dismiss specific neurological complications. Third, since the COVID-19 pandemic has not yet over, the results and underlying mechanisms of this disease would certainly be much more impressive than we expect.Unlike some systematic reviews that reviewed the majority of studies 

The results of this systematic review and meta-analysis showed that Taken together, patients with COVID-19 who indicated neurological symptoms should be taken seriously and should receive early treatment to prevent undesirable events.

The authors declare that they have no conflict of interest.

Mehr, Sajjad Abbasimoghaddam, Amirhosein Shekartabar, Mohsen Heidary, and Saeed Khoshnood contributed to revising and final approval of the version to be published. All authors agreed and confirmed the manuscript for publication.

All the data in this review are included in the article.

https://orcid.org/0000-0002-9839-5017